Christopher Peetz - 15 Mar 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
15 Mar 2025
Transactions value $
-$1,206,122
Form type
4
Filing time
18 Mar 2025, 21:30:05 UTC
Previous filing
04 Mar 2025
Next filing
08 Aug 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +50K +43.13% 166K 15 Mar 2025 Direct F1
transaction MIRM Common Stock Sale -$1.21M -27.3K -16.44% $44.21 139K 17 Mar 2025 Direct F2
holding MIRM Common Stock 209K 15 Mar 2025 By The Peetz Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Performance Restricted Stock Units Options Exercise $0 -50K -66.67% $0.00 25K 15 Mar 2025 Common Stock 50K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
F3 The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026.